GLP-1 Medications Explained: How the Class Works

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

GLP-1 — glucagon-like peptide-1 — is an incretin hormone secreted by L-cells of the small intestine in response to food intake. It plays a central role in post-meal insulin release, gastric emptying, and satiety signaling. The GLP-1 receptor agonist drug class mimics this hormone's effects pharmacologically. This article covers what GLP-1 is, how the receptor agonist class works, what compounds are FDA-approved as of April 2026, and the upstream genetic variables.

What GLP-1 actually is

Native GLP-1 is a 30- to 31-amino-acid peptide secreted by intestinal L-cells. After release, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and engages central satiety circuits in the hypothalamus. Native GLP-1 has a very short half-life (about 2 minutes) because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4).

How GLP-1 receptor agonist drugs work

GLP-1 receptor agonist medications are engineered to resist DPP-4 degradation, extending half-life from minutes to days or weeks. They bind the same GLP-1 receptor as the native hormone — driving the same downstream effects on insulin secretion, glucagon suppression, gastric emptying, and satiety. Tirzepatide-based compounds add agonism at the GIP receptor (a related incretin receptor), which is one of the key molecular distinctions in the class as of April 2026.

FDA-approved GLP-1 medications as of April 2026

The FDA-approved GLP-1 receptor agonist class includes: exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to OSA, 2024). Investigational compounds in late-stage development include retatrutide (a GIP/GLP-1/glucagon triple agonist) and orforglipron (an oral non-peptide small-molecule GLP-1 receptor agonist).

Why genetic context matters in the GLP-1 pathway

GLP-1 receptor agonists work by engaging a receptor pathway that has natural genetic variation. GLP1R (the GLP-1 receptor gene itself; variants influence receptor density and downstream incretin signaling efficiency) is the most direct upstream variable. FTO (fat-mass and obesity-associated gene; common variants influence appetite regulation and adiposity set-point), MC4R (melanocortin-4 receptor; variants influence satiety signaling in the hypothalamus and total energy intake), and TCF7L2 (transcription factor 7-like 2; variants influence insulin secretion and incretin response) shape adjacent metabolic biology. These variants are pathway-level — they do not predict response to any one compound, but they describe the metabolic terrain on which any GLP-1 compound has to work.

PlexusDx offers GLP-1 receptor agonists through its Weight Management Protocols, including Glp-1 Receptor Agonists protocol. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in GLP1R, FTO, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1?.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Weight Management Protocols protocol inside the Weight Management Protocols collection. To start upstream with the genetic context, take the Precision Peptide Genetic Test first.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone secreted by intestinal L-cells in response to food intake. GLP-1 stimulates glucose-dependent insulin release, slows gastric emptying, and signals satiety to the brain. The GLP-1 receptor agonist drug class mimics these effects.

Are GLP-1 medications and GLP-1 inhibitors the same thing?

No — they are opposites. GLP-1 receptor agonists activate the GLP-1 receptor and produce the GLP-1 hormonal effects. There is no widely-used class called "GLP-1 inhibitors" in current clinical practice. (DPP-4 inhibitors are different — they reduce breakdown of native GLP-1 but do not activate the receptor directly.)

How are GLP-1 receptor agonists administered?

Most FDA-approved GLP-1 receptor agonists are administered as subcutaneous injections (weekly or daily depending on the compound). Rybelsus is the only FDA-approved oral option as of April 2026. Compounded oral GLP-1 protocols exist through licensed compounding pharmacy pathways — not FDA-approved as branded products.

Does genetic testing tell me which GLP-1 to take?

No. The Precision Peptide Genetic Test does not predict which GLP-1 medication is right for any individual. It analyzes pathway-level variants in GLP1R, FTO, and MC4R and other genes that shape baseline GLP-1 biology — context for the broader protocol conversation with a healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education